PURPOSE: Cancer treatment by conventional radiotherapy is limited by normal tissue side-
effects. Fibroblasts as “non-target” stromal cell type are considered as strong promoter of
tumor growth and for developing a therapy resistant phenotype. Regarding application of
novel molecular therapeutics combined with radiotherapy, evaluation of a specific targeted
molecule in both tumor and normal cells is mandatory for efficacy and tolerability
assessment. Previous work showed integrin-linked kinase (ILK), a mediator of β-integrin …